GAVI facts and figures

in page functions

Statistics measuring Gavi, the Vaccine Alliance's impact on global immunisation

Every year, academics, journalists, teachers and students ask for statistics detailing Gavi's results since the Vaccine Alliance was established in 2000. Sourcing the Gavi Secretariat and members of the Vaccine Alliance, including WHO, UNICEF and civil society organisations, these key facts and figures list Gavi's achievements to date as well as demonstrating the Vaccine Alliance's catalytic role within global immunisation.


The Vaccine Alliance has helped strengthen health systems and immunisation services in more than 60 countries and increased injection safety.

Source: Gavi


Since the first human papillomavirus (HPV) vaccine demonstration project in Kenya in 2013, 300,000 girls have been vaccinated with Gavi support – a figure expected to rise to one million by the end of 2015.The programmes are the first step towards national introduction; Gavi has already started to fund Rwanda’s national HPV programme.

Source: Gavi


In September 2014, Nepal became the first country to introduce inactivated polio vaccine (IPV) with Gavi support. By the end of the year, 64 countries had applied for Vaccine Alliance support.

Source: Gavi

22 million

Since 2007, Gavi support for a 2nd dose of measles vaccine has helped countries immunise 22 million children through national programmes; in addition, Gavi-funded measles campaigns have helped vaccinate another 67 million children in countries considered at high risk of measles outbreaks.

Source: WHO/UNICEF 2015

140 million

By the end of 2014, Gavi-funded measles-rubella catch-up campaigns, targeting the next generation of mothers and children aged 9 months to 14 years, had reached 140 million people.

Source: WHO/UNICEF 2015

88 million

Starting in 2011, Gavi-supported mass prevention campaigns have protected 88 million people in 14 “high-risk” countries. We have also helped 17 countries introduce yellow fever vaccine through routine immunisation since 2000.

Source: Gavi


Since its creation in 2013, the global oral cholera vaccine has been used to vaccinate more than 600,000 people; in 2014, doses were allocated to Ethiopia, Guinea, Haiti, Nepal and South Sudan.

Source: Gavi

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

+215 million

By the end of 2014, 15 countries in the African meningitis belt had collectively immunised more than 215 million people against meningitis A with support from Gavi.

Source: WHO 2014


Gavi support is available to the 73 poorest countries in the world. Over 20 countries are projected to graduate from Gavi’s support by 2020.

Source: Gavi

1 in 5

In total, 1 in 5 children in Gavi-supported countries are still missing out on the basic package of childhood vaccines. 95% of children do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015


7 million

Since its launch in 2000, Gavi has helped developing countries to prevent 7 million future deaths from hepatitis B, Haemophilus influenzae type b (Hib), measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever.

Source: Gavi / Bill & Melinda Gates Foundation

500 million

Since 2000, Gavi support has contributed to the immunisation of an additional 500 million children.


47 million

By the end of 2014, Vaccine Alliance support had contributed to immunising 47 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions more than 1 year ahead of schedule.

Source: WHO/UNICEF 2015


Gavi support will assist countries to immunise a further 243 million children between 2011 and 2015.

Source: Gavi


Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

73 countries

Gavi support is available to the 73 poorest countries in the world. By the end of 2013, 22 countries were projected to graduate from Gavi’s support by 2020.

Source: Gavi

US$ 9.9 billion

The total commitments as of 30 June 2015 are US$ 9.9 billion. This includes current commitments from year 2000 up to 2020 for both country programmes and investment cases.

Source: Gavi

+20 million

Vaccine Alliance support had contributed to immunising over 20 million children against rotavirus diarrhoea by the end of 2014. More countries (16) introduced than ever before - the largest number of introductions of a single vaccine in a calendar year.

Source: WHO/UNICEF 2015

3.9 million

The Vaccine Alliance’s support for vaccines will contribute to averting an estimated 3.9 million future deaths between 2011 and 2015.

Source: Gavi


The weighted average price of pentavalent vaccine per dose has dropped from US$ 3.56 in 2003 to US$ 1.90 in 2014.

Source: Gavi

1.5 million

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

5 -> 16

From 5 to 16 vaccine manufacturers supplying Gavi – from 1 to 10 based in emerging markets.

2001: 5 vaccine manufacturers - 1 based in an emerging market;
2014: 16 vaccine manufacturers– 10 based in emerging markets.

Source: Gavi

19 million

Nearly 19 million infants remain unimmunised in the world each year.

Source: WHO/UNICEF 2015

close icon

modal window here